--- title: "BioNexus Gene Lab | 10-K: FY2025 Revenue: USD 7.425 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/282747718.md" datetime: "2026-04-14T21:28:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282747718.md) - [en](https://longbridge.com/en/news/282747718.md) - [zh-HK](https://longbridge.com/zh-HK/news/282747718.md) --- # BioNexus Gene Lab | 10-K: FY2025 Revenue: USD 7.425 M Revenue: As of FY2025, the actual value is USD 7.425 M. EPS: As of FY2025, the actual value is USD -1.607. EBIT: As of FY2025, the actual value is USD -3.029 M. ### Consolidated Financial Performance #### Gross Profit Total Gross Profit decreased from $1,289,521 in fiscal year 2024 to $1,085,217 in fiscal year 2025. #### Operating Expenses Total Operating Expenses decreased by 9% from - $4,935,696 in fiscal year 2024 to - $4,482,399 in fiscal year 2025. Sales and Marketing expenses decreased from - $2,030,684 in 2024 to - $1,736,331 in 2025. Research and Development expenses increased slightly from - $47,511 in 2024 to - $50,670 in 2025. General and Administrative expenses decreased from - $1,832,968 in 2024 to - $1,535,452 in 2025. Share-based Compensation increased from - $141,000 in 2024 to - $794,770 in 2025. Provision for Expected Credit Losses decreased from - $883,533 in 2024 to - $271,211 in 2025. #### Loss from Operations Total Loss from Operations increased by 88% from - $1,573,702 in fiscal year 2024 to - $2,965,065 in fiscal year 2025. #### Finance Costs Total Finance Costs decreased from - $21,146 in fiscal year 2024 to - $19,542 in fiscal year 2025. #### Net Loss Attributable to Common Shareholders Total Net Loss increased from - $1,598,342 in fiscal year 2024 to - $2,984,607 in fiscal year 2025. #### Comprehensive Loss Total Comprehensive Loss increased from - $1,476,048 in fiscal year 2024 to - $2,550,356 in fiscal year 2025. #### Liquidity and Capital Resources - Working Capital decreased from $5,479,146 at December 31, 2024, to $4,927,781 at December 31, 2025. - Net Cash Used in Operating Activities was - $1,838,382 in 2025, compared to - $2,093,260 in 2024. - Net Cash Generated from Investing Activities was $944,751 in 2025, compared to $418,202 in 2024. - Net Cash Generated from Financing Activities was $298,841 in 2025, compared to $3,975 in 2024. - Cash and Cash Equivalents, End of Financial Year, were $2,486,383 in 2025, compared to $2,886,966 in 2024. #### Research and Development Consolidated R&D Budget was $50,670 in 2025, compared to $47,511 in 2024. #### Income Taxes - Net Operating Loss (NOL) Carryforwards (USA) were $8,938,122 as of December 31, 2025. - Net Operating Loss (NOL) Carryforwards (Malaysia) were $2,567,801 as of December 31, 2025. - Valuation Allowance for Deferred Tax Assets increased by $2,203,533 in 2025 to $11,607,175. ### Segmented Financial Performance #### Provision for Genomic Screening Services (MRNA Scientific) - Gross Profit increased from $8,753 in 2024 to $9,754 in 2025. - Gross Margin Percentage decreased from 54.5% in 2024 to 51.1% in 2025. - Other Income increased by 45.1% from $122,951 in 2024 to $178,452 in 2025. - Operating Expenses increased from - $366,848 in 2024 to - $397,851 in 2025. - Loss from Operations decreased from - $235,144 in 2024 to - $209,645 in 2025. - Finance Costs increased from - $11,795 in 2024 to - $12,709 in 2025. - Net Loss Attributable to Common Shareholders decreased from - $246,939 in 2024 to - $222,354 in 2025. - Segment Assets decreased from $2,652,754 in 2024 to $2,281,947 in 2025. - Addition to Non-Current Assets decreased significantly from $150,881 in 2024 to $1,382 in 2025. #### Trading of Industrial Chemicals (Chemrex) - Gross Profit decreased from $1,280,768 in 2024 to $1,075,463 in 2025. - Gross Margin Percentage improved from 13.6% in 2024 to 14.6% in 2025. - Other Income decreased by 87% from $1,949,522 in 2024 to $253,665 in 2025. - Operating Expenses decreased from - $3,424,310 in 2024 to - $2,375,539 in 2025. - Loss from Operations increased from - $194,020 in 2024 to - $1,046,411 in 2025. - Finance Costs decreased from - $9,072 in 2024 to - $6,645 in 2025. - Net Loss Attributable to Common Shareholders increased from - $206,586 in 2024 to - $1,053,056 in 2025. - Segment Assets decreased from $6,788,302 in 2024 to $4,577,690 in 2025. - Addition to Non-Current Assets decreased from $221,844 in 2024 to $35,589 in 2025. #### Investment Holding - Operating Expenses increased from - $1,144,538 in 2024 to - $1,709,009 in 2025. - Loss from Operations increased from - $1,144,538 in 2024 to - $1,709,009 in 2025. - Finance Costs decreased from - $279 in 2024 to - $188 in 2025. - Net Loss Attributable to Common Shareholders increased from - $1,144,817 in 2024 to - $1,709,197 in 2025. - Segment Assets increased from $992,792 in 2024 to $2,393,147 in 2025. - Addition to Non-Current Assets remained $0 for both 2024 and 2025. ### Outlook / Guidance BioNexus Gene Lab Corp. plans to address internal control deficiencies and establish a group-level risk and compliance framework. The company expects to continue developing its VitaGuard™ Minimal Residual Disease (MRD) platform in Southeast Asia and expand into digital healthcare markets, including co-investment projects with the Malaysian government. Potential revenue acceleration is anticipated through strategic alliances, mergers, or acquisitions facilitated by its investment banking advisor. ### Related Stocks - [BGLC.US](https://longbridge.com/en/quote/BGLC.US.md) ## Related News & Research - [Su-Leng Tan Lee Discloses Investment at BioNexus Gene Lab Corp with 11.5% Stake](https://longbridge.com/en/news/295980100.md) - [BioNexus Gene Lab files initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd](https://longbridge.com/en/news/295275069.md) - [Corpay, Inc. Reaffirms 2025 Form 10-K Risk Factors, Urging Investors to Revisit Disclosures Amid Evolving Market Conditions](https://longbridge.com/en/news/295497227.md) - [Envoy Medical’s Limited Disclosures Put Spotlight on 10-K Risk Factors for Investors](https://longbridge.com/en/news/295491580.md) - [Extreme Networks Inc FY 2026: Revenue $1.28B, EPS $0.31— 10-K Summary](https://longbridge.com/en/news/296091264.md)